Advertisement

Topics

. @ImmuneDesign to halt Phase III trial and “deprioritize” development of #Cancer vaccine candidate CMB305, following disappointing Phase II results: http://ow.ly/BdNQ30mcVzV 

17:55 EDT 12 Oct 2018 | Genetic Engineering News

. to halt Phase III trial and “deprioritize” development of vaccine candidate CMB305, following disappointing Phase II results: http://ow.ly/BdNQ30mcVzV 

Original Article: . @ImmuneDesign to halt Phase III trial and “deprioritize” development of #Cancer vaccine candidate CMB305, following disappointing Phase II results: http://ow.ly/BdNQ30mcVzV 

NEXT ARTICLE

More From BioPortfolio on ". @ImmuneDesign to halt Phase III trial and “deprioritize” development of #Cancer vaccine candidate CMB305, following disappointing Phase II results: http://ow.ly/BdNQ30mcVzV "

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...